Study: Femara bests tamoxifen in avoiding breast cancer return

12/28/2005 | Guardian (London), The

A large study of the Novartis drug letrozole, marketed as Femara, shows it is more useful than tamoxifen for treating women at risk of having breast cancer return. The two drugs were compared in a study of 8,000 women, and those women whose breast cancer had spread to their lymph nodes experienced 29% fewer cases of their cancer returning when treated with letrozole.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC